HER2-low metastatic breast cancer: management and prognosis of an emerging breast cancer subtype in a real-world setting, anglais PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download HER2-low metastatic breast cancer: management and prognosis of an emerging breast cancer subtype in a real-world setting, anglais PDF full book. Access full book title HER2-low metastatic breast cancer: management and prognosis of an emerging breast cancer subtype in a real-world setting, anglais by Ombline de Calbiac. Download full books in PDF and EPUB format.
Author: Ombline de Calbiac
Publisher:
ISBN:
Category :
Languages : en
Pages : 108
Get Book Here
Book Description
Contexte. Le cancer du sein HER2-faible (HER2 IHC 1+/2+ en l'absence d'amplification du gène HER2 en FISH) est une nouvelle entité, avec des traitements dédiés émergents. Peu de données ont été rapportées sur ce sous-type. A partir d'une base de données nationale, nous avons évalué le pronostic et l'efficacité des traitements chez les patientes atteintes d'un cancer du sein métastatique HER2-faible en vie réelle. Méthode. La plateforme ESME sur le cancer du sein métastatique (NCT03275311) est une base de données regroupant 18 centres de lutte contre le cancer français. Elle inclut les patients atteints d'un cancer du sein métastatique nouvellement diagnostiqué ayant initié un traitement entre 2008 et 2016 dans l'un des centres. Les cancers du sein HER2-faibles ont été comparés à la population HER2-0, en termes de survie sans progression en première ligne métastatique (SSP1) et de survie globale (SG). Résultats. Parmi les 15 054 cancers du sein métastatiques dits HER2 "négatifs", 4 671 (31%) et 10 383 (69%) étaient respectivement HER2-faibles et HER2-0. Les cancers du sein HER2-faibles étaient pour la plupart RH+ (N=4 083 ; 87,4%). L'âge médian des patientes était de 61 ans [22-103], le grade tumoral était principalement II/III (89,6%). Les cancers du sein HER2-faibles étaient plus fréquemment métastatiques de novo (37,3% versus 27,8% pour les cancers HER2-0; p
Author: Ombline de Calbiac
Publisher:
ISBN:
Category :
Languages : en
Pages : 108
Get Book Here
Book Description
Contexte. Le cancer du sein HER2-faible (HER2 IHC 1+/2+ en l'absence d'amplification du gène HER2 en FISH) est une nouvelle entité, avec des traitements dédiés émergents. Peu de données ont été rapportées sur ce sous-type. A partir d'une base de données nationale, nous avons évalué le pronostic et l'efficacité des traitements chez les patientes atteintes d'un cancer du sein métastatique HER2-faible en vie réelle. Méthode. La plateforme ESME sur le cancer du sein métastatique (NCT03275311) est une base de données regroupant 18 centres de lutte contre le cancer français. Elle inclut les patients atteints d'un cancer du sein métastatique nouvellement diagnostiqué ayant initié un traitement entre 2008 et 2016 dans l'un des centres. Les cancers du sein HER2-faibles ont été comparés à la population HER2-0, en termes de survie sans progression en première ligne métastatique (SSP1) et de survie globale (SG). Résultats. Parmi les 15 054 cancers du sein métastatiques dits HER2 "négatifs", 4 671 (31%) et 10 383 (69%) étaient respectivement HER2-faibles et HER2-0. Les cancers du sein HER2-faibles étaient pour la plupart RH+ (N=4 083 ; 87,4%). L'âge médian des patientes était de 61 ans [22-103], le grade tumoral était principalement II/III (89,6%). Les cancers du sein HER2-faibles étaient plus fréquemment métastatiques de novo (37,3% versus 27,8% pour les cancers HER2-0; p
Author: Ouissam Al Jarroudi
Publisher: Springer Nature
ISBN: 303133602X
Category : Medical
Languages : en
Pages : 371
Get Book Here
Book Description
This book focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters. Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management. The closing chapters deal with the challenges of conducting research in the era of precision medicine for cancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike.
Author: Adnan Aydiner
Publisher: Springer
ISBN: 3030167925
Category : Medical
Languages : en
Pages : 806
Get Book Here
Book Description
This second updated volume on breast cancer provides a comprehensive overview of its clinical management and current therapies. Updated to reflect the changes in breast cancer staging, the progress in immunotherapy approaches, as well as the latest guidelines for therapies, this book brings readers up to speed with the latest therapeutic regimens in breast cancer and provides an in-depth account of current and new therapeutic approaches. The most important phase III trials, high quality meta-analysis, consensus reports and guidelines are extensively discussed in this new edition and provide the reader with the most up-to-date information. Divided in themed parts, the book examines invasive breast cancer, pre-operative systemic therapy surgical management and recurrence among others, thus providing an in-depth account of breast cancer at the clinical stage. Among the themed parts are a section dedicated to special therapeutic problems, such as breast cancer in older women, Paget’s disease and phyllodes tumors and a section on supportive and follow-up care. By adopting a multidisciplinary approach to breast cancer, this book is a must-have for breast cancer practitioners. With a high number of colored illustrations and edited by highly experienced clinicians, this work enables readers to gain an interdisciplinary perspective on breast diseases. Contributions from an international team of experts present invaluable insight into clinical practice across different settings. Covering both theoretical and practical aspects of breast cancer, this is a highly informative and carefully presented book which will appeal to an international audience of medical, radiation and surgical oncologists.
Author: William J. Gradishar
Publisher: Springer Science & Business Media
ISBN: 9780792378907
Category : Medical
Languages : en
Pages : 230
Get Book Here
Book Description
The optimal management of breast cancer patients relies on the expertise of a team of medical specialists including radiologists, surgeons, radiation therapists and medical oncologists. Much of the progress in breast cancer management made over the last several years reflects the translation of observations made in the laboratory to the clinic. Critically evaluating the impact of new treatment approaches relies on a commitment to well-designed clinical trials. In this volume, Advances in Breast Cancer Management, a renowned group of breast cancer experts have been asked to provide their perspective on management issues that directly effect patients on a day-to-day basis. Dr. Melody Cobleigh discusses the consequences of estrogen deprivation and the ways of ameliorating secondary symptoms and the potential long-term morbidity. Drs. Haigh and Guiliano review the sentinel lymph node biopsy technique including results from their extensive experience. Dr. Abram Recht places into perspective the potential benefit of post-mastectomy radiotherapy and reviews recent trials that address this issue. Dr. Dennis Slamon takes from us from the laboratory to the clinic in explaining the development of Herceptin as a paradigm for therapy targeted to specific molecular characteristics of breast cancer tumor cells. Drs. Nieto, Shpall, Crump and Pritchard offer different perspectives on the future of high-dose chemotherapy with stem cell transplantation as a treatment for breast cancer patients. Drs.
Author: James L. Weese
Publisher: Elsevier Health Sciences
ISBN: 0323932509
Category : Medical
Languages : en
Pages : 233
Get Book Here
Book Description
Because most cancer care is delivered in the community setting, Breast Cancer, edited by Dr. James L. Weese, looks at the management of breast cancer through the lens of multidisciplinary pathways focused on evidence-based, real-world care of breast cancer patients in the community. A multidisciplinary team of expert authors provides state-of-the-art guidance from the perspective of community practitioners using an evidence-based model, clearly showing the thought processes used to make treatment decisions in today’s breast cancer management. Discusses all the latest breakthrough therapies for breast cancer, including chemotherapeutic, molecular, and immunologic agents, as well as new developments in precision-based medicine, pharmacology, breast cancer surgery, breast and lymphatic reconstruction, radiation therapy, and more. Provides strategies for targeted radiation therapy and conservative breast surgery for contemporary breast cancer treatment Features more than 200 high-quality figures throughout, including pathways, anatomic, radiographic, and graphic images. Models a consistent, team-based thought process used at leading academic institutions to foster consistent decision making applied to the community setting. Includes key points at the beginning of each chapter that highlight essential concepts and topics An ideal resource for practicing medical oncologists, surgical oncologists, and radiation therapists, trainees and practitioners in related fields, and oncology nurses and case managers. Any additional digital ancillary content may publish up to 6 weeks following the publication date.
Author: Guido Bocci
Publisher: Springer
ISBN: 3662436043
Category : Medical
Languages : en
Pages : 302
Get Book Here
Book Description
This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.
Author: Frederick L, Greene
Publisher: Springer Science & Business Media
ISBN: 1475736568
Category : Medical
Languages : en
Pages : 386
Get Book Here
Book Description
The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms.
Author: Monica Castiglione
Publisher: Springer Science & Business Media
ISBN: 0387751157
Category : Medical
Languages : en
Pages : 483
Get Book Here
Book Description
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author: World Health Organization
Publisher:
ISBN: 9789241565462
Category : Medical instruments and apparatus
Languages : en
Pages : 246
Get Book Here
Book Description
This is the model list and clearing house of appropriate, basic, and priority medical devices based on the list of clinical interventions selected from clinical guidelines on prevention, screening, diagnosis, treatment, palliative care, monitoring, and end of life care. This publication addresses medical devices that can be used for the management of cancer and specifically describes medical devices for six types of cancer: breast, cervical, colorectal, leukemia, lung, and prostate. This book is intended for ministries of health, public health planners, health technology managers, disease management, researchers, policy makers, funding, and procurement agencies and support and advocacy groups for cancer patients.
Author: Giampietro Gasparini
Publisher: Springer Science & Business Media
ISBN: 159259915X
Category : Medical
Languages : en
Pages : 335
Get Book Here
Book Description
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
